Research Analysts Offer Predictions for ELDN FY2026 Earnings

Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN – Free Report) – Equities research analysts at Noble Financial upped their FY2026 earnings estimates for shares of Eledon Pharmaceuticals in a report issued on Monday, November 16th. Noble Financial analyst R. Leboyer now forecasts that the company will post earnings of ($0.58) per share for the year, up from their previous estimate of ($0.74). The consensus estimate for Eledon Pharmaceuticals’ current full-year earnings is ($0.74) per share. Noble Financial also issued estimates for Eledon Pharmaceuticals’ Q4 2026 earnings at ($0.20) EPS.

Eledon Pharmaceuticals (NASDAQ:ELDN – Get Free Report) last released its quarterly earnings data on Friday, November 13th. The company reported ($0.18) earnings per share for the quarter, topping the consensus estimate of ($0.19) by $0.01.

Several other equities analysts have also commented on ELDN. Wall Street Zen raised Eledon Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Saturday. Rodman & Renshaw started coverage on Eledon Pharmaceuticals in a report on Tuesday, July 21st. They issued a “buy” rating and a $12.00 price target on the stock. Finally, Weiss Ratings raised Eledon Pharmaceuticals from a “sell (d-)” rating to a “sell (d)” rating in a report on Monday, November 9th. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $12.00.

View Our Latest Stock Analysis on ELDN

Eledon Pharmaceuticals Stock Up 0.5%

Shares of NASDAQ ELDN opened at $1.98 on Wednesday. The firm’s 50-day moving average price is $2.52 and its two-hundred day moving average price is $3.11. Eledon Pharmaceuticals has a 52-week low of $1.35 and a 52-week high of $4.49. The stock has a market capitalization of $167.23 million, a P/E ratio of -2.71 and a beta of 0.95.

Hedge Funds Weigh In On Eledon Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in ELDN. Ancora Advisors LLC bought a new position in Eledon Pharmaceuticals in the 3rd quarter worth approximately $38,000. Goldman Sachs Group Inc. raised its stake in Eledon Pharmaceuticals by 2.0% during the 3rd quarter. Goldman Sachs Group Inc. now owns 2,561,285 shares of the company’s stock valued at $6,480,000 after acquiring an additional 50,977 shares in the last quarter. Jump Financial LLC raised its stake in Eledon Pharmaceuticals by 91.3% during the 3rd quarter. Jump Financial LLC now owns 40,708 shares of the company’s stock valued at $103,000 after acquiring an additional 19,427 shares in the last quarter. Russell Investments Group Ltd. raised its stake in Eledon Pharmaceuticals by 212.6% during the 3rd quarter. Russell Investments Group Ltd. now owns 127,933 shares of the company’s stock valued at $324,000 after acquiring an additional 87,010 shares in the last quarter. Finally, StoneX Group Inc. acquired a new position in Eledon Pharmaceuticals during the 3rd quarter worth $29,000. 56.77% of the stock is currently owned by institutional investors and hedge funds.

Eledon Pharmaceuticals Company Profile

(Get Free Report)

Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing therapies for serious diseases involving the immune system. The company’s research focuses on modulating immune responses to help address conditions such as organ transplant rejection and amyotrophic lateral sclerosis (ALS). Its lead investigational product, tegoprubart, is an antibody that targets CD40 ligand, a protein involved in immune-system activation. Eledon is studying tegoprubart as a potential treatment to reduce rejection following organ transplantation and in research involving ALS.

Featured Stories

Earnings History and Estimates for Eledon Pharmaceuticals (NASDAQ:ELDN)

Receive News & Ratings for Eledon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eledon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.